Patient Co-payment and Adherence to Statins: A Review and Case Studies
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
This study aims to review the international literature about whether there is an association between co-payment and statin adherence, and to present case studies to illustrate the impact of a reduction in patient co-payment associated with generic drugs on improving therapy adherence.
Studies that examined the impact of patient co-payment on statin adherence were identified in PubMed, Cochrane Central Register of Controlled Trials and EconLit up to January 2013. A standardized data extraction form was completed for each included study, collecting information about country, sample, setting, adherence measure, design, results about the impact of co-payment on statin adherence, and methodological quality. Two cases from the outpatient clinic of one the authors (PRS) were added.
The literature supported a statistically significant negative association between co-payment and statin adherence. This association appeared to be influenced by the absolute level of co-payments, the size of the co-payment change, whether co-payment increases or decreases, the time horizon over which the impact of a co-payment change is examined, the type of drug for which co-payment changes (e.g. generic or branded drug), the availability of alternative drugs and switching behaviour. Two case studies illustrated that cost issues are important to patients and that patient adherence to statin therapy improved following a switch to generic statins.
Current studies have demonstrated that statin adherence is influenced by co-payment and a range of patient, physician and pharmacy characteristics. Nevertheless, the power of these models to explain the variation in adherence remains limited.
- Osterberg, L, Blaschke, T (2005) Adherence to medication. N Engl J Med 353: pp. 487-497 CrossRef
- Eaddy, MT, Cook, CL, O’Day, K, Burch, SP, Cantrell, CR (2012) How patient cost-sharing trends affect adherence and outcomes: a literature review. P T 37: pp. 45-55
- Sinnott, SJ, Buckley, C, O’Riordan, D, Bradley, C, Whelton, H (2013) The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. Plos One 8: pp. e64914 CrossRef
- Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev. 2008:CD007017.
- Gibson, TB, Ozminkowski, RJ, Goetzel, RZ (2005) The effects of prescription drug cost sharing: a review of the evidence. Am J Manage Care 11: pp. 730-740
- Goldman, DP, Joyce, GF, Zheng, Y (2007) Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298: pp. 61-69 CrossRef
- Sturm H, Austvoll-Dahlgren A, Aaserud M, Oxman AD, Ramsay C, Vernby A, et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst Rev. 2007:CD006731.
- Choudhry, NK, Avorn, J, Glynn, RJ, Antman, EM, Schneeweiss, S, Toscano, M (2011) Full coverage for preventive medications after myocardial infarction. N Engl J Med 365: pp. 2088-2097 CrossRef
- Hsu, J, Price, M, Huang, J, Brand, R, Fung, V, Hui, R (2006) Unintended consequences of caps on Medicare drug benefits. N Engl J Med 354: pp. 2349-2359 CrossRef
- Choudhry, NK, Fischer, MA, Avorn, JL, Lee, JL, Schneeweiss, S, Solomon, DH (2012) The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol 60: pp. 1817-1824 CrossRef
- Cohen, JD, Brinton, EA, Ito, MK, Jacobson, TA (2012) Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 6: pp. 208-215 CrossRef
- Peterson, AM, McGhan, WF (2005) Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics 23: pp. 13-25 CrossRef
- Tamblyn, R, Laprise, R, Hanley, JA, Abrahamowicz, M, Scott, S, Mayo, N (2001) Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285: pp. 421-429 CrossRef
- Bitton, A, Choudhry, NK, Matlin, OS, Swanton, K, Shrank, WH (2013) The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med 126: pp. 357 CrossRef
- Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration 2011. Available from: URL: www.cochrane-handbook.org.
- GRADE Working Group. Grading of recommendations assessment, development and evaluation. GRADE Working Group 2013. Available from: URL: http://www.gradeworkinggroup.org/.
- Schneeweiss, S, Patrick, AR, Maclure, M, Dormuth, CR, Glynn, RJ (2007) Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 115: pp. 2128-2135 CrossRef
- Coombs, JH, Cornish, L, Hiller, P, Smith, DG (2002) Compliance and refill pattern behavior with HMG-CoA reductase inhibitors after acute myocardial infarction. Manag Care Interface 15: pp. 54-58
- Choudhry, NK, Fischer, MA, Avorn, J, Schneeweiss, S, Solomon, DH, Berman, C (2010) At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood) 29: pp. 1995-2001 CrossRef
- Schultz, JS, O’Donnell, JC, McDonough, KL, Sasane, R, Meyer, J (2005) Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manage Care 11: pp. 306-312
- Ye, X, Gross, CR, Schommer, J, Cline, R, St Peter, WL (2007) Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther 29: pp. 2748-2757 CrossRef
- Ellis, JJ, Erickson, SR, Stevenson, JG, Bernstein, SJ, Stiles, RA, Fendrick, AM (2004) Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 19: pp. 638-645 CrossRef
- Gibson, TB, Mark, TL, McGuigan, KA, Axelsen, K, Wang, S (2006) The effects of prescription drug copayments on statin adherence. Am J Manage Care 12: pp. 509-517
- Gibson, TB, Mark, TL, Axelsen, K, Baser, O, Rublee, DA, McGuigan, KA (2006) Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manage Care 12: pp. SP11-SP19
- Ray, WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158: pp. 915-920 CrossRef
- Chernew, ME, Shah, MR, Wegh, A, Rosenberg, SN, Juster, IA, Rosen, AB (2008) Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood) 27: pp. 103-112 CrossRef
- Frank, MB, Fendrick, AM, He, Y, Zbrozek, A, Holtz, N, Leung, S (2012) The effect of a large regional health plan’s value-based insurance design program on statin use. Med Care 50: pp. 934-939 CrossRef
- Goldman, DP, Joyce, GF, Karaca-Mandic, P (2006) Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manage Care 12: pp. 21-28
- Landsman, PB, Yu, W, Liu, X, Teutsch, SM, Berger, ML (2005) Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manage Care 11: pp. 621-628
- Maciejewski, ML, Farley, JF, Parker, J, Wansink, D (2010) Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood) 29: pp. 2002-2008 CrossRef
- Sedjo, RL, Cox, ER (2008) Lowering copayments: impact of simvastatin patent expiration on patient adherence. Am J Manage Care 14: pp. 813-818
- Cramer, JA, Roy, A, Burrell, A, Fairchild, CJ, Fuldeore, MJ, Ollendorf, DA (2008) Medication compliance and persistence: terminology and definitions. Value Health 11: pp. 44-47 CrossRef
- Peterson, AM, Nau, DP, Cramer, JA, Benner, J, Gwadry-Sridhar, F, Nichol, M (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10: pp. 3-12 CrossRef
- Chan, DC, Shrank, WH, Cutler, D, Jan, S, Fischer, MA, Liu, J (2010) Patient, physician, and payment predictors of statin adherence. Med Care 48: pp. 196-202 CrossRef
- Doshi, JA, Zhu, J, Lee, BY, Kimmel, SE, Volpp, KG (2009) Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 119: pp. 390-397 CrossRef
- Karaca-Mandic P, Swenson T, Abraham JM, Kane RL. Association of medicare part D medication out-of-pocket costs with utilization of statin medications. Health Serv Res. 2013;48(4):1311–33.
- Maciejewski, ML, Bryson, CL, Perkins, M, Blough, DK, Cunningham, FE, Fortney, JC (2010) Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Manage Care 16: pp. e20-e34
- Pedan, A, Varasteh, L, Schneeweiss, S (2007) Analysis of factors associated with statin adherence in a hierarchical model considering physician, pharmacy, patient, and prescription characteristics. J Manag Care Pharm 13: pp. 487-496
- Goldman, DP, Joyce, GF, Escarce, JJ, Pace, JE, Solomon, MD, Laouri, M (2004) Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291: pp. 2344-2350 CrossRef
- Lemstra, M, Blackburn, D, Crawley, A, Fung, R (2012) Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol 28: pp. 574-580 CrossRef
- Mann, DM, Woodward, M, Muntner, P, Falzon, L, Kronish, I (2010) Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother 44: pp. 1410-1421 CrossRef
- Choudhry, NK, Avorn, J, Antman, EM, Schneeweiss, S, Shrank, WH (2007) Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood) 26: pp. 186-194 CrossRef
- Choudhry, NK, Patrick, AR, Antman, EM, Avorn, J, Shrank, WH (2008) Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation 117: pp. 1261-1268 CrossRef
- Dalem, J, Krass, I, Aslani, P (2012) Interventions promoting adherence to cardiovascular medicines. Int J Clin Pharm 34: pp. 295-311 CrossRef
- Patient Co-payment and Adherence to Statins: A Review and Case Studies
Cardiovascular Drugs and Therapy
Volume 28, Issue 1 , pp 99-109
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Case study
- Industry Sectors
- Author Affiliations
- 1. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Onderwijs en Navorsing 2, Herestraat 49, P.O. Box 521, 3000, Leuven, Belgium
- 2. Department of Cardiovascular Medicine, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium